Eledon Pharmaceuticals Inc. has announced that it will host a Research and Development Day in New York City on July 9, 2025. The event will focus on Eledon's lead investigational candidate, tegoprubart, particularly its clinical development in organ and cell transplantation. The event will feature members of Eledon's executive team and several leading experts in transplantation, who will discuss topics such as the ongoing Phase 2 BESTOW trial and unmet needs in solid organ transplantation. Additional sessions will address the evolution of clinical endpoints and strategic opportunities in islet cell transplantation and xenotransplantation. The program will conclude with a live Q&A session. Presentation materials and a live webcast of the event will be accessible on the company's website. Results from the studies will be presented during the event.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。